Different Impact Of Antiretroviral Drugs On Bone Differentiation In An In Vitro Model
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Different Impact Of Antiretroviral Drugs On Bone Differentiation In An In Vitro Model
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 116, Issue 10, Pages 2188-2194
Publisher
Wiley
Online
2015-03-25
DOI
10.1002/jcb.25169
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bone Mineral Density Effects of Randomized Regimen and Nucleoside Reverse Transcriptase Inhibitor Selection from ACTG A5142
- (2013) Jeannie S. Huang et al. HIV CLINICAL TRIALS
- Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study
- (2013) Aoife G. Cotter et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Prevalence and Risk Factors of Low Bone Mineral Density in Korean HIV-Infected Patients: Impact of Abacavir and Zidovudine
- (2013) Hee-Sung Kim et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
- (2012) Emanuele Focà et al. BMC INFECTIOUS DISEASES
- Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts
- (2012) Rongrong Zhang et al. BONE
- Comparison of Bone and Renal Effects In HIV-infected Adults Switching to Abacavir or Tenofovir Based Therapy in a Randomized Trial
- (2012) Thomas A. Rasmussen et al. PLoS One
- Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
- (2012) Hila Haskelberg et al. PLoS One
- Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens
- (2011) Todd T Brown et al. ANTIVIRAL THERAPY
- Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
- (2011) Grace A. McComsey et al. JOURNAL OF INFECTIOUS DISEASES
- Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase
- (2010) Tanya Welz et al. AIDS
- Tenofovir treatment of primary osteoblasts alters gene expression profiles: Implications for bone mineral density loss
- (2010) Iwen F. Grigsby et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study
- (2010) Hans‐Jürgen Stellbrink et al. CLINICAL INFECTIOUS DISEASES
- Metabolic bone disease in HIV infection
- (2009) Marco Borderi et al. AIDS
- Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts
- (2009) Iwen F. Grigsby et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Fracture Prevalence among Human Immunodeficiency Virus (HIV)-InfectedVersusNon-HIV-Infected Patients in a Large U.S. Healthcare System
- (2008) Virginia A. Triant et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fibroblast Growth Factor Signaling Uses Multiple Mechanisms To Inhibit Wnt-Induced Transcription in Osteoblasts
- (2008) D. Ambrosetti et al. MOLECULAR AND CELLULAR BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started